Search results (117)
« Back to PublicationsPredicting Salmonella Typhi incidence using prevalence metrics from sentinel studies of community-onset bloodstream infections: a secondary analysis of observational data.
Journal article
Hagedoorn NN. et al, (2026), Vaccine, 85
Maternal views on RSV vaccination in the UK's second season.
Journal article
O'Hagan S. et al, (2026), Lancet Infect Dis, 26, e209 - e211
The association between vaccine coverage and herd protection: exploratory analyses of a cluster-randomised trial of Vi conjugate vaccine.
Journal article
Zhang Y. et al, (2026), EClinicalMedicine, 94
Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials.
Journal article
Bijukchhe SM. et al, (2026), Lancet Infect Dis
The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trial.
Journal article
Liatsikos K. et al, (2026), Lancet Microbe, 7
Maternal perspectives on the RSV vaccine (Abrysvo): a thematic analysis of survey findings from the first season of implementation in England and Scotland.
Journal article
O'Hagan S. et al, (2026), Arch Dis Child
Predicting Salmonella Typhi incidence using prevalence metrics from sentinel studies of community-onset bloodstream infections
Preprint
Hagedoorn N. et al, (2026)
SARS-CoV-2-Specific Immune Responses to Vaccination in Children and Adolescents with Suppressed Immune Systems: A Prospective, Observational Study.
Journal article
Brugha R. et al, (2026), J Pediatr, 289
Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against Salmonella Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocol.
Journal article
Paganotti Vicentine M. et al, (2026), BMJ Open, 16
Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial.
Journal article
Kelly E. et al, (2026), J Infect, 92
